Ventus' PROVENT Sleep Apnea Therapy is runner-up at the The Wall Street Journal Technology Innovation Awards

NewsGuard 100/100 Score

Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.

"We are excited to be recognized by The Wall Street Journal for our PROVENT Sleep Apnea Therapy," said John McCutcheon, President and Chief Executive Officer at Ventus Medical. "We are proud of this innovative treatment and the potential benefit it brings to the more than 50 million Americans who have obstructive sleep apnea and those not satisfied with standard therapies. We continue our commitment to developing innovative solutions for people affected by sleep-disordered breathing."

According to The Wall Street Journal, winners were selected from nearly 500 nominations across numerous categories from nearly 20 countries. Of those, more than 180 nominations cleared preliminary screening and were passed on for review by a panel of judges comprised of research institutions, venture capital firms and other companies. Judges evaluated whether innovations were truly groundbreaking and also looked at whether their application would be particularly useful in a time of economic hardship. Only seven percent of entries screened by the judges received an award.

www.ventusmedical.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hypoglossal nerve stimulation offers hope for pediatric Down syndrome patients with OSA